The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits
Open accessAbstract
Huntington's disease (HD) is a neurodegenerative disorder caused by expansion of a CAG repeat in the huntingtin ( Htt ) gene. HD is autosomal dominant and, in theory, amenable to therapeutic RNA silencing. We introduced cholesterol-conjugated small interfering RNA duplexes (cc-siRNA) targeting human Htt mRNA (siRNA- Htt ) into mouse striata that also received adeno-associated virus containing either expanded (100 CAG) or wild-type (18 CAG) Htt cDNA encoding huntingtin (Htt) 1–400. Adeno-associated virus delivery to striatum and overlying cortex of the mutant Htt gene, but not the wild type, produced neuropathology and motor deficits. Treatment with cc-siRNA- Htt in mice with mutant Htt prolonged survival of striatal neurons, reduced neuropil aggregates, diminished inclusion size, and lowered the frequency of clasping and footslips on balance beam. cc-siRNA- Htt was designed to target human wild-type and mutant Htt and decreased levels of both in the striatum. Our findings indicate that a single administration into the adult striatum of an siRNA targeting Htt can silence mutant Htt , attenuate neuronal pathology, and delay the abnormal behavioral phenotype observed in a rapid-onset, viral transgenic mouse model of HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Self-citationShah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Asymmetry in the Assembly of the RNAi Enzyme Complex
Schwarz, D. S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., & Zamore, P. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00759-1 · Cited by 2,922
Self-citationAggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Self-citationTherapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Self-citationDavies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,181
Self-citationInclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595
Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
Yamamoto, A., Lucas, J. J., & Hen, R. (2000) · Cell · doi:10.1016/s0092-8674(00)80623-6 · Cited by 1,067
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology
Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., & Li, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02522.1999 · Cited by 914
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.-P., Carraway, R., Reeves, S. A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90346-1 · Cited by 749
Self-citationHarper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia
Xia, H., Mao, Q., Eliason, S. L., Harper, S. Q., Martins, I. H., Orr, H. T., Paulson, H. L., Yang, L., Kotin, R. M., & Davidson, B. L. (2004) · Nature Medicine · doi:10.1038/nm1076 · Cited by 652
Neurological abnormalities in a knock-in mouse model of Huntington's disease
Lin, C.-H. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.2.137 · Cited by 592
Ralph, G. S., Radcliffe, P. A., Day, D. M., Carthy, J. M., Leroux, M. A., Lee, D. C. P., Wong, L.-F., Bilsland, L. G., Greensmith, L., Kingsman, S. M., et al. (2005) · Nature Medicine · doi:10.1038/nm1205 · Cited by 506
Raoul, C., Abbas-Terki, T., Bensadoun, J.-C., Guillot, S., Haase, G., Szulc, J., Henderson, C. E., & Aebischer, P. (2005) · Nature Medicine · doi:10.1038/nm1207 · Cited by 464
Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
Li, B.-J., Tang, Q., Cheng, D., Qin, C., Xie, F. Y., Wei, Q., Xu, J., Liu, Y., Zheng, B.-J., Woodle, M. C., et al. (2005) · Nature Medicine · doi:10.1038/nm1280 · Cited by 433
Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model
Singer, O., Marr, R. A., Rockenstein, E., Crews, L., Coufal, N. G., Gage, F. H., Verma, I. M., & Masliah, E. (2005) · Nature Neuroscience · doi:10.1038/nn1531 · Cited by 428
Allele-specific silencing of dominant disease genes
Miller, V. M., Xia, H., Marrs, G. L., Gouvion, C. M., Lee, G., Davidson, B. L., & Paulson, H. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1231012100 · Cited by 400
siRNA relieves chronic neuropathic pain
Dorn, G. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh044 · Cited by 381
Induction of the interferon response by siRNA is cell type– and duplex length–dependent
Reynolds, A., Anderson, E. M., Vermeulen, A., Fedorov, Y., Robinson, K., Leake, D., Karpilow, J., Marshall, W. S., & Khvorova, A. (2006) · RNA · doi:10.1261/rna.2340906 · Cited by 317
Kim, M., Lee, H.-S., LaForet, G., McIntyre, C., Martin, E. J., Chang, P., Kim, T. W., Williams, M., Reddy, P. H., Tagle, D., et al. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-03-00964.1999 · Cited by 305
Self-citationLaforet, G. A., Sapp, E., Chase, K., McIntyre, C., Boyce, F. M., Campbell, M., Cadigan, B. A., Warzecki, L., Tagle, D. A., Reddy, P. H., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09112.2001 · Cited by 290
Self-citationRodriguez-Lebron, E., Denovan-Wright, E. M., Nash, K., Lewin, A. S., & Mandel, R. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.006 · Cited by 275
de Almeida, L. P., Ross, C. A., Zala, D., Aebischer, P., & Déglon, N. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03473.2002 · Cited by 224
Thakker, D. R., Natt, F., Hüsken, D., Maier, R., Müller, M., van der Putten, H., Hoyer, D., & Cryan, J. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406214101 · Cited by 211
Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery
Zuccato, C., Liber, D., Ramos, C., Tarditi, A., Rigamonti, D., Tartari, M., Valenza, M., & Cattaneo, E. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.01.001 · Cited by 196
Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA
Wang, Y.-L., Liu, W., Wada, E., Murata, M., Wada, K., & Kanazawa, I. (2005) · Neuroscience Research · doi:10.1016/j.neures.2005.06.021 · Cited by 191
Adeno-Associated Virus (AAV) Vectors in the CNS
McCown, T. (2005) · Current Gene Therapy · doi:10.2174/1566523054064995 · Cited by 184
Lack of interferon response in animals to naked siRNAs
Heidel, J. D., Hu, S., Liu, X. F., Triche, T. J., & Davis, M. E. (2004) · Nature Biotechnology · doi:10.1038/nbt1038 · Cited by 183
Knock-in mouse models of Huntington’s disease
Menalled, L. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.465 · Cited by 178
Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis
Ding, H., Schwarz, D. S., Keene, A., Affar, E. B., Fenton, L., Xia, X., Shi, Y., Zamore, P. D., & Xu, Z. (2003) · Aging Cell · doi:10.1046/j.1474-9728.2003.00054.x · Cited by 170
Self-citationComparison of siRNA-induced off-target RNA and protein effects
Alemán, L. M., Doench, J. G., & Sharp, P. A. (2007) · RNA · doi:10.1261/rna.352507 · Cited by 164
rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse
Machida, Y., Okada, T., Kurosawa, M., Oyama, F., Ozawa, K., & Nukina, N. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.141 · Cited by 139
Stereology: A Practical Primer for Neuropathology
Hyman, B. T., Gómez‐Isla, T., & Irizarry, M. C. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199804000-00001 · Cited by 82
Expressing short hairpin RNAs in vivo
Snøve, O., & Rossi, J. J. (2006) · Nature Methods · doi:10.1038/nmeth927 · Cited by 68
Cheng, K., Ye, Z., Guntaka, R. V., & Mahato, R. I. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100347 · Cited by 63
mRNA for low density lipoprotein receptor in brain and spinal cord of immature and mature rabbits.
Hofmann, S. L., Russell, D. W., Goldstein, J. L., & Brown, M. S. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.17.6312 · Cited by 60
Lewis, D. L., & Wolff, J. A. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)92020-4 · Cited by 56
Cited by
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Mitochondria in neuroplasticity and neurological disorders
Mattson, M. P., Gleichmann, M., & Cheng, A. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.010 · Cited by 1,081
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
“…needs to be delivered by direct intraparenchymal injections, and therapeutic correction is limited to only a small portion of the striatum immediately adjacent to the sites of injection (Boudreau et al., 2009; DiFiglia et al., 2007; Drouet et al., 2009; Harper et al., 2005; McBride et al., 2008).”
Influential
Metadata
- Authors
- DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R. K., Rajeev, K. G., Manoharan, M., Sah, D. W. Y., Zamore, P. D., & Aronin, N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-10-23
- Volume
- 104
- Issue
- 43
- Pages
- 17204-17209
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2068422066
- Cited by
- 415
- References
- 42
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.